Trial Search Results

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously untreated, locally advanced or metastatic, unresectable soft tissue sarcoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:



  • Drug: AMG 655
  • Other: Placebo
  • Drug: Doxorubicin


Phase 1/Phase 2


Inclusion Criteria:

   - Histologically or cytologically confirmed soft tissue sarcoma

   - Locally advanced, recurrent, or metastatic, unresectable disease

   - Measurable disease according to modified RECIST

   - ECOG performance status of 0 or 1

   - Men or women at least 18 years of age

   - Adequate hematological, renal, hepatic, and coagulation function

Exclusion Criteria:

   - Prior treatment with anthracyclines

   - Uncontrolled cardiovascular disease

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
Not Recruiting